Recursion delivered a genome‑scale microglia phenomap to Roche/Genentech as part of their multi‑year collaboration, triggering a $30 million milestone payment and providing a 46‑million image dataset designed to accelerate target discovery in neurodegeneration. The map is intended to identify microglial targets across diseases such as Alzheimer’s and Parkinson’s. Separately, Regeneron struck a collaboration with ModeX (Gary Nabel’s multispecific antibody company) to co‑develop multispecific antibodies, expanding Regeneron’s multispecifics push. Both moves underscore pharma’s growing reliance on AI/phenotypic maps and multispecific platforms to replenish pipelines across oncology and neuroscience. Operationally, partnerships now combine AI phenotyping, high‑content screening, and multispecific engineering to shorten target‑to‑lead timelines. Companies should expect milestone structures tied to data delivery, target validation, and IND‑enabling activities. For R&D teams: integrating large phenotypic datasets into translational pipelines will require bioinformatic capacity and cross‑discipline validation to convert AI signals into actionable therapeutic programs.